Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies. - Kobayashi RH; Litzman J; Melamed I; Mandujano JF; Kobayashi AL; Ritchie B; Geng B; Atkinson TP; Rehman S; Höller S; Turpel-Kantor E; Kreuwel H; et al. (Clinical and experimental immunology, 2022)